InsidersTradesSigma
Follow the 환인제약 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 환인제약 has published 20 insider filings. Market capitalisation: €181.9bn. The latest transaction was disclosed on 11 May 2026 (Other). Among the most active insiders: 이원범. The full history is accessible without an account.
20
Insider Decl.
n/a
Thresholds
n/a
2 ops.
Buy Volume
n/a
2 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,563 of 29,063 companies
63.5
score / 100
Value67
Quality60
FCF yld1.5%
Earn yld7.2%
EV/EBITDA7.7x
ROE5.1%
Gross mgn34%
Net mgn5.3%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 May 2026
Declarations20 total
0KRXDART:20230908000530
0KRXDART:20230810000490
0KRXDART:20230726000204
0KRXDART:20230608000120
0KRXDART:20220705000186
0KRXDART:20210827000693
0KRXDART:20210702000328
0KRXDART:20210405002639
20 of 20 declarations
About 환인제약
환인제약 is a South Korean pharmaceutical company focused on the development and manufacturing of medications. It is listed on the XKRX stock market.